Inhibiting CDK8/CDK19 in CRC cell lines lowers the levels of glucose transporters, glucose uptake, and glycolytic capacity and reduces cell proliferation and anchorage-independent growth. The gene discussed is CDK19; the disease is colorectal carcinoma.